AVPR2 antagonism with tolvaptan alters medullary cell responses and attenuates kidney injury
Tolvaptan may reduce kidney injury-related inflammation and stress responses in a mouse model, but its clinical relevance in humans is unclear.
Where it sits
this study against the rest of the vasopressin corpusSummary and findings
This study examined the effects of the AVPR2 antagonist Tolvaptan on kidney responses in male mice following ischemia-reperfusion injury and cisplatin administration. It reported that Tolvaptan reduced urine and medullary tissue osmolality and altered gene expression related to stress and inflammation. The findings suggest potential benefits of AVPR2 antagonism in kidney injury contexts.
Abstract
<h4>ABSTRACT</h4> <h4>Introduction</h4> Arginine vasopressin receptor 2 (AVPR2) signaling regulates kidney collecting duct signaling and urinary concentration, but the kidney’s cell-type-specific responses to its pharmacological inhibition and their relevance to non-cystic kidney injury remain incompletely characterized. <h4>Methods</h4> We examined physiological and transcriptional responses to the AVPR2 antagonist Tolvaptan in uninjured male mice and assessed tissue outcomes after unilateral ischemia-reperfusion injury (IRI) and repeated cisplatin administration. Analyses included renal tissue osmolality measurements, single nucleus and bulk RNA sequencing of kidney tissues, quantitative PCR, in situ hybridization, and histology. <h4>Results</h4> In uninjured kidneys, Tolvaptan reduced urine and medullary tissue osmolality and altered transcription predominantly in medullary collecting-duct populations, including lower expression of selected stress-associated and proinflammatory genes. Following IRI, Tolvaptan-treated mice exhibited attenuated expression of inflammatory and monocyte recruitment genes, reduced macrophage accumulation in the renal medulla, and diminished fibrotic remodeling. In cisplatin-induced kidney injury Tolvaptan reduced tubular injury markers and inflammatory activation in the outer medulla. <h4>Conclusions</h4> Tolvaptan attenuates medullary tubular stress responses and post-injury inflammation and fibrosis. These findings extend the effects of pharmacological AVPR2 antagonism beyond water homeostasis to tissue-level responses in non-cystic kidney injury. <h4>TRANSLATIONAL STATEMENT</h4> Acute kidney injury can lead to persistent inflammation and fibrotic remodeling, yet the contribution of medullary Avpr2 signaling to these processes remains poorly understood. In mice, treatment with the clinically used Avpr2 antagonist Tolvaptan reduced medullary osmolality and modulated stress-associated tubular transcriptomes. Tolvaptan treatment initiated before injury reduced selected inflammatory and tissue remodeling endpoints in experimental kidney injury. These findings support further investigation of pharmacological AVPR2 antagonism in non-cystic kidney disease.
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.